Marc Grasso
Equibles does not estimate personal net worth.
Get an email with a short summary when Kyverna Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get KYTX alertsAbout Marc Grasso
Marc Grasso is recorded as CFO at Kyverna Therapeutics, Inc. (KYTX). The newest filing on record that lists Marc Grasso as CFO at Kyverna Therapeutics, Inc. (KYTX) is dated April 13, 2026. Earlier roles on record: CFO at Kura Oncology, Inc. (KURA) until February 4, 2022 and CFO at Alector, Inc. (ALEC) until June 20, 2025. Kyverna Therapeutics, Inc. reported in an 8-K filed May 18, 2026 that Marc Grasso resigned as principal financial officer, effective May 18, 2026. Kyverna Therapeutics, Inc. reported in an 8-K filed May 18, 2026 that Marc Grasso resigned as principal accounting officer, effective May 18, 2026. Kyverna Therapeutics, Inc. reported in an 8-K filed June 30, 2025 that Marc Grasso was appointed Chief Financial Officer, effective June 30, 2025. Equibles holds 4 filed executive changes naming Marc Grasso; each is listed under recent activity with its source filing. The proxy statement of Kyverna Therapeutics, Inc. reports total compensation of $1,663,536 for Marc Grasso in fiscal 2025, including a base salary of $256,961. Disclosed compensation is on record for 8 fiscal years. Marc Grasso has spoken on 7 earnings calls across 1 company, most recently for Kura Oncology, Inc. on November 4, 2021. Kyverna Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Marc Grasso spoke on are classified in the Healthcare sector. Other leadership on record at Kyverna Therapeutics, Inc. includes Warner Biddle (CEO and Board Member), Christi Shaw (Chairman and Board Member), Greg Martini (CFO) and 7 others.
“Effective upon the appointment of Mr. Martini as the Company’s Chief Financial Officer, Marc Grasso, M.D. ceased serving as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.”
“Effective upon the appointment of Mr. Martini as the Company’s Chief Financial Officer, Marc Grasso, M.D. ceased serving as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.”
Marc Grasso on recent calls
“I'll provide a brief overview of our financial results for the third quarter 2021, along with reiterating our guidance for the full year 2021. I invite you to review our 10-Q filed today for a more detailed discussion.”
“I'll provide a brief overview of our financial results for the second quarter of 2021, along with guidance for the full year 2021. I invite you to review our 10-Q filed today for a more detailed discussion.”
“I'll provide a brief overview of our financial results here on the call and invite you to review our 10-Q filed today for a more detailed discussion. Research and development expenses for the first quarter of 2021 were $20.3 million compared to $12.6 million for the first quarter of 2020.”
“I'll provide a brief overview of our financial results here on the call and invite you to review our 10-K filed today for a more detailed discussion. Research and development expenses for the fourth quarter of 2020 were $17.5 million, compared to $13.5 million for the fourth quarter of 2019.”
“I'll provide a brief overview of our financial results here on the call and invite you to review our 10-Q filed today for a more detailed discussion. Research and development expenses for the third quarter of 2020 were $16.6 million compared to $12.5 million for the third quarter of 2019.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 13, 2026
-
Start not stated–2022-02-04
-
Start not stated–2025-06-20
Company network
KURA
Biotechnology · Healthcare
CFO
Leadership on record at Kyverna Therapeutics, Inc.
- Warner Biddle CEO, Board Member
- Christi Shaw Chairman, Board Member
- Greg Martini CFO
- Gregory Martini CFO, Chief Accounting Officer
- Marc Grasso, M.D. CFO
- Mayo Pujols CTO
- Andrew Miller Board Member
- Andrew Miller, Ph.D. Board Member
- Beth Seidenberg Board Member
- Fred E. Cohen Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kyverna Therapeutics, Inc. (KYTX) | Chief Financial Officer | $256,961 | $1,663,536 |
| 2024 | Alector, Inc. (ALEC) | Chief Financial Officer | $514,777 | $1,687,869 |
| 2023 | Alector, Inc. (ALEC) | Chief Financial Officer | $496,800 | $1,715,846 |
| 2022 | Kura Oncology, Inc. (KURA) | Former Chief Financial Officer and Chief Business Officer | $45,608 | $1,694,717 |
| 2022 | Alector, Inc. (ALEC) | Chief Financial Officer | $432,923 | $6,011,780 |
| 2021 | Kura Oncology, Inc. (KURA) | Former Chief Financial Officer and Chief Business Officer | $446,300 | $4,356,608 |
| 2020 | Kura Oncology, Inc. (KURA) | Former Chief Financial Officer and Chief Business Officer | $415,000 | $1,589,108 |
| 2019 | Kura Oncology, Inc. (KURA) | Former Chief Financial Officer and Chief Business Officer | $387,750 | $2,112,282 |
| 2018 | Kura Oncology, Inc. (KURA) | M.D.^(^^4)^ Chief Financial Officer and Chief Business Officer | $136,876 | $3,634,267 |